Vivian Barry is a Senior Scientist in the Pathobiology group at Gilead Sciences. She began her career in molecular biology and immunology research areas at DNAX and Genentech. She eventually ventured into histopathology research and became the manager of the immunohistochemistry team at Arresto Biosciences in 2008. Vivian joined Gilead in 2011, with the acquisition of Arresto, and has been managing the IHC/Pathology group at Gilead since that time. Over the years, she has focused on building the histopathology lab and has introduced various machinery and techniques to enhance the delivery of high quality IHC and CISH data. Her team focuses on target validation in both human tissues and animal models, assists in determining mechanism of action of therapeutics and small molecules, and is involved in IND-enabling studies. She collaborates with investigators across Gilead's departments; these projects include virology, immunology, oncology, and fibrotic diseases. Vivian received her Bachelor of Science and Master of Science degrees at the University of San Francisco, and has recently received her MBA from the Golden Gate University, San Francisco.